Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Vomiting 3Nausea 3Lymphoma 2Delirium 2Sarcoma, Alveolar Soft Part 1Recurrence 1Pain 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 8Oxaliplatin 6Carboplatin 5Vincristine 4Radiotherapy 4Mental Status and Dementia Tests 4Leucovorin 4Amifostine 4Taxes 3Sodium Chloride 3Procarbazine 3Methotrexate 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Cytarabine 3Cyclophosphamide 3Cisplatin 3xaliproden 2glucarpidase 2Surveys and Questionnaires 2Rituximab 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Psychiatric Rehabilitation 2Prednisolone 2Magnesium Sulfate 2Folfox protocol 2Duloxetine Hydrochloride 2Doxorubicin 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurotoxicity Syndromes × Lorazepam × Clear all
NCT01949662 2026-02-13

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
93 enrolled 14 charts
Other hematologic neoplasm

Delirium, Hematologic Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡